Journal article
Neurometabolite levels in alcohol use disorder patients during baclofen treatment and prediction of relapse to heavy drinking
Frontiers in Psychiatry, Vol.9, 412
2018
Appears in Thompson Institute Research Collection
Abstract
Background and aims: Baclofen, a GABAb agonist, is used as a treatment for alcohol dependence. We aimed to examine brain metabolites following administration of baclofen or placebo in alcohol dependent individuals enrolled in a randomised placebo-controlled trial. Methods: Participants included 31 alcohol dependent individuals (recent drinking: N = 16; and abstinent: N = 15) who had received daily baclofen (BAC = 20) or placebo (PL = 11) for at least 2 weeks (average 17 days). Using in vivo proton magnetic resonance spectroscopy (1H-MRS), spectra from the right parietal lobe were analysed to obtain measures of GABA, Glutamate (Glu), Glutathione (GSH) and N-Acetyl Apartate (NAA) 120 minutes following administration of PL, 10 mg or 25 mg BAC. Results: When weighting alcohol dependent participants according to recent alcohol consumption (within 24 hours), there were significant differences between BAC and PL on parietal concentrations of GSH (p < 0.01) and NAA (p < 0.05). Multiple linear regression revealed a significant predictive effect of GSH on heavy drinking days at 12 week follow-up (Model: F =14.28, R2 = 0.85; GSH: B = -1.22, p = 0.01) and also percentage days abstinent at 12 week follow-up (Model: F =6.50, R2 = 0.72; GSH: B = 0.99, p = 0.06). Conclusion: Our data suggests that the effect of baclofen may be mediated by increased parietal concentrations of the antioxidant GSH and NAA in recently drinking alcohol dependent patients. GSH/Cr levels were also predictive of improved drinking outcomes in the trial and suggests a role for neural oxidative stress in alcohol use disorder.
Details
- Title
- Neurometabolite levels in alcohol use disorder patients during baclofen treatment and prediction of relapse to heavy drinking
- Authors
- Kirsten Morley (Author) - University of SydneyJim Lagopoulos (Author) - University of the Sunshine Coast - Thompson InstituteWarren Logge (Author) - University of SydneyKate Chitty (Author) - University of SydneyAndrew Baillie (Author) - University of SydneyPaul Haber (Author) - University of Sydney
- Publication details
- Frontiers in Psychiatry, Vol.9, 412; 8
- Publisher
- Frontiers Research Foundation
- Date published
- 2018
- DOI
- 10.3389/fpsyt.2018.00412
- ISSN
- 1664-0640
- Copyright note
- Copyright © 2018 Morley, Lagopoulos, Logge, Chitty, Baillie and Haber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Organisation Unit
- University of the Sunshine Coast, Queensland; Thompson Institute
- Language
- English
- Record Identifier
- 99450753102621
- Output Type
- Journal article
Metrics
29 File views/ downloads
568 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Psychiatry
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites